Activity Overview
The management of esophagogastric adenocarcinoma has evolved substantially with the introduction of effective targeted and immunologic therapies. However, these therapies are appropriate mainly for patients with specific biomarkers, necessitating careful coordination among the multidisciplinary team to ensure proper tissue stewardship and testing, which in turn allows for appropriate treatment selection and sequencing, as well as management and mitigation of adverse events.
In this webcast, experts in the management of esophagogastric adenocarcinoma discuss the principles for molecular testing in these cancers, with a particular focus on identifying HER2-positive disease, as well as outlining key decision points for treatment. These points will be discussed in the context of patient case scenarios that highlight challenges in the management of HER2-positive esophagogastric cancers.
This educational activity is an archive of the live virtual symposium held on April 23, 2026.
Target Audience
This educational program is primarily directed toward medical oncologists, molecular pathologists, radiologists, gastroenterologists, advanced practice providers, and nurses who are involved in the management of patients with advanced or metastatic gastroesophageal adenocarcinomas (GEA).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Apply best practices for HER2 biomarker testing in patients with GEA to guide timely, individualized treatment decisions
- Incorporate the latest evidence on HER2-directed therapies into individualized treatment plans for patients with advanced GEA
Yelena Y. Janjigian, MD
Carroll and Milton Petrie Chair
Professor and Chief Attending, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AbbVie, AlphaSights, Amerisource Bergen, Arcus Biosciences, AskGene Pharma, Astellas, AstraZeneca, Basilea Pharmaceutica, Bayer, BeOne, Boehringer Ingelheim, Bristol Myers Squibb, Clinical Care Options, Daiichi Sankyo, Debbie’s Dream Foundation, eChinaHealth, Ed Med Resources (OncInfo), Eisai, Eli Lilly, Geneos Therapeutics, Gilead Sciences, GlaxoSmithKline, Guardant Health, H.C. Wainwright & Co, Health Advances, HMP Global, i3 Health, Imedex, Imugene, Inspirna, Lynx Health, Mashup Media, Master Clinician Alliance, Merck, Merck Serono, Mersana Therapeutics, OncoDaily, Oncology News, Paradigm Medical Communications, PeerMD, PeerView Institute, Pfizer, Research to Practice, Sanofi Genzyme, Seagen, Silverback Therapeutics, Suzhou Liangyihui Network Technology Co, Talem Health, Total CME, WebMD, Zymeworks; Grant/Research Funding: Arcus Biosciences, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Coherus, Cycle for Survival, Department of Defense, Eli Lilly, Fred’s Team, Genentech/Roche, Inspirna, Merck, NCI, Stand Up 2 Cancer, Transcenta; Ownership interests in privately held companies: OncoDaily
Michal F. Segal, BSN, OCN
Clinical Trials Nurse
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Speakers Bureau: Astellas Pharma Inc.
Amitabh Srivastava, MD
Attending, Memorial Hospital
Member, Memorial Sloan Kettering Cancer Center
Director, GI Pathology Fellowship Program
Department of Pathology
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Amitabh Srivastava, MD, has no relevant financial relationships with ineligible companies.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.